Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Requests for Frequent Delivery Abating in Tohoku: Wholesalers
March 28, 2011
- Oncology Strategies of Top-four Japanese Pharmaceutical Companies
March 28, 2011
- Nichi-Iko Acquires Additional Shares from Aprogen
March 28, 2011
- JSMI Presents List of OTC Drugs Available Free of Charge
March 28, 2011
- Takeda Suspends PII Trial for Anti-obesity Drug in US
March 28, 2011
- 14 Hokoku-hinmoku Included in NHI Price List
March 28, 2011
- MTPC Ties Up with Kyoto Univ. to Develop Drugs for Kidney Disease
March 28, 2011
- Korosho Calls For Reasonable Ordering Practices from Med. Institutions, Pharmacies
March 28, 2011
- JMA to Dispatch JMATs to Disaster Area
March 28, 2011
- Both AZ, Plaintiffs Appeal to High Court
March 28, 2011
- NIRS Dispatches 3 Teams to Fukushima
March 28, 2011
- JAMS to Promote Industry-Academia Alliances by Increasing COI Transparency
March 28, 2011
- Insulin Manufacturers Ensure Stable Supply of Their Products
March 28, 2011
- Astellas Applies for Marketing Approval for Bixalomer
March 28, 2011
- Domestic, Foreign Drugmakers Up Efforts to Assist Quake Victims
March 28, 2011
- Wholesalers Striving to Fulfill Mission despite Risk
March 28, 2011
- Exal Approved for LCH as Additional Indication: Nippon Kayaku
March 28, 2011
- 2 Treatments Recommended for Approval as Senshin-iryo
March 28, 2011
- Gas Shortage Hurting Distribution in Tohoku: Wholesalers
March 28, 2011
- Higher Dosage Approved for Meropen: DSP
March 28, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…